Taltz revenue trends
In 3Q17, Eli Lilly’s (LLY) Taltz generated revenues of $151.3 million compared to $32.5 million in 3Q16. In 3Q17, Eli Lilly’s Taltz witnessed 9% growth on year-over-year (or YoY) basis. In 3Q17, in the US and international markets, Taltz generated revenues of $131.3 million and $20.0 million, respectively, compared to $32.0 million and $0.5 million in 3Q16.
Taltz reported revenues of $386.7 million in the first nine months of 2017. Year-to-date, Taltz reported revenues of $343.6 million and $43.1 million, respectively, in US and international markets in the first nine months of 2017.
In December 2017, the US Food and Drug Administration (or FDA) approved Eli Lilly’s Taltz for the treatment of active psoriatic arthritis. Taltz received its first approval for treatment of adults with moderate-to-severe plaque psoriasis who need systemic therapy or phototherapy.
In November 2017, Eli Lilly presented the long-term data from its phase three SPIRIT-P2 extension trial. In the trial, the majority of Taltz-treated patients demonstrated improvement in disease activity of psoriatic arthritis at 52 weeks.
Taltz competes with AbbVie’s (ABBV) Humira, Celgene’s (CELG) Otezla, Johnson & Johnson’s (JNJ) Stelara, and Novartis’s Cosentyx. In 3Q17, Otezla, Stelara, and Cosentyx reported revenues of $308 million, $1.1 billion, and $556 million, respectively.
The US FDA approval for new indications could boost the sales growth of Taltz. The revenue growth of Eli Lilly’s Taltz could boost the Vanguard Total Stock Market ETF (VTI). Eli Lilly makes up about ~0.28% of VTI’s total portfolio holding.